Clay B Siegall is the co-founded of Seattle Genetics, a company that deals with the development of different targeted cancer therapies. His passion for the company started from drug development, vigorous research, and a passion for helping patients. Since the company’s inception, he has made strides in the development of antibody-drug conjugates and in securing their approvals from the FDA. Under his leadership, Seattle Genetics has obtained different licenses for their ADC technology that has generated more than $350 million.
Before he founded Seattle Genetics, Siegall worked at Bristol-Myers Squibb, a pharmaceutical research institute and the National Cancer Center between the years 1991 to 1997. Within the same time, he was also part of the board of directors at the Washington Roundtable, Alder Biopharmaceuticals, and Ultragenyx Pharmaceuticals. His continued efforts made him earn the 2013 University of Maryland alumnus for natural science, math, and computer, as well as the 2012 Earnest & Young Entrepreneur of the year.
Dr. Clay Siegall believes that the systemic chemotherapies that are common in today’s treatment are a thing of the past. He firmly believes that with the advancements of targeted therapies, we should see more of these drugs in the years to come. He notes in one of the interviews that his keen interest in cancer treatment came while he was still studying zoology at the University of Maryland. While conducting amputation and radical surgery, he was convinced that there had to be a better way.
He also didn’t have much when he started out as a senior researcher at Bristol. Most of the profits gained and recognition earned went back to the institute. There are different ways in which Siegall makes money, and one is through selling his proprietary drug. In fact, one of their approved antibody drug conjugates was one of the first ADC that was ever approved by the FDA and is now approved for three indications.